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Introduction: Although positron emission tomography computed 
tomography (PET-CT) has been widely used for small-cell lung can-
cer (SCLC) staging, no study has examined the clinical impact of 
PET staging in limited-stage (LS) SCLC.
Methods: We identified patients with LS-SCLC treated definitively 
with concurrent chemoradiation. Outcomes were assessed using the 
Kaplan–Meier approach, Cox regression, and competing risks method.
Results: We treated 54 consecutive LS-SCLC patients with concur-
rent chemoradiation from January 2002 to August 2010. Forty under-
went PET, 14 did not, and all underwent thoracoabdominopelvic CT 
and magnetic resonance imaging neuroimaging. Most patient char-
acteristics were balanced between the comparison groups, includ-
ing age, race, sex, bone scanning, median dosage, and performance 
status. More number of PET-staged patients presented with nodal 
metastases (p = 0.05). Median follow-up was similar for PET-staged 
and non–PET-staged patients (p = 0.59). Median overall survival 
from diagnosis in PET-staged patients was 32 versus 17 months in 
patients staged without PET (p = 0.03), and 3-year survival was 47% 
versus 19%. Median time-to-distant failure was 29 versus 12 months 
(p = 0.04); median time-to-local failure was not reached versus 16 
months (p = 0.04). On multivariable analysis, PET staging (odds ratio 
[OR] = 0.24; p = 0.04), performance status (OR = 1.89; p = 0.05), 
and N-stage (OR = 4.94; p < 0.01) were associated with survival.
Conclusion: LS-SCLC patients staged with PET exhibited improved 
disease control and survival when compared with non–PET-staged 
LS-SCLC patients. Improved staging accuracy and better identifica-
tion of intrathoracic disease may explain these findings, underscoring 
the value of PET-CT in these patients.
Key Words: Small-cell lung cancer, Positron emission tomography, 
Positron emission tomography computed tomography, Staging, Stage 
migration, Radiation, Chemoradiation.
(J Thorac Oncol. 2013;8: 899-905)
This study suggests that positron emission tomography computed tomography (PET-CT) improves staging accu-
racy and intrathoracic disease identification in limited-stage 
small-cell lung cancer (LS-SCLC), which translates into an 
improvement in clinical outcome in these patients. Although 
retrospective, these data suggest that PET-CT should be rou-
tinely used in the staging of newly diagnosed patients with 
SCLC. These data need to be further confirmed in a prospec-
tive clinical trial.
Each year, 13% of all newly diagnosed lung cancer 
patients are diagnosed with SCLC.1 Approximately 39% of 
patients with SCLC are diagnosed with LS disease treated 
with chemotherapy and definitive radiation therapy.1 Staging 
information is essential because of the high propensity for 
metastatic disease in SCLC, and the identification of metas-
tases can spare patients from the toxicity associated with 
thoracic radiotherapy. Furthermore, in those patients who do 
receive radiotherapy, knowing the exact extent of intratho-
racic disease may permit more accurate treatment volume 
delineation.
Until 2011, the National Comprehensive Cancer Network 
(NCCN) recommended a (99m)Tc-MDP bone scan as 
part of the initial evaluation of all newly diagnosed SCLC 
patients. However, in 2012, the NCCN began recommending 
18-fluorodeoxyglucose (18F) PET-CT in lieu of bone scan 
in its initial workup algorithm. No prospective trial has 
compared the sensitivity or specificity of PET-CT with 
(99m)Tc-MDP scanning in the detection of metastatic bone 
disease in SCLC. In 2012, Lee et al., in the Annals of Nuclear 
Medicine, retrospectively reported sensitivity and specificity 
of 100% for metastatic bone disease on a per-patient basis with 
PET-CT, which compared with 37% and 92%, respectively, 
with bone scan. The study also observed 100% positive and 
negative predictive values for PET as opposed to 69% and 
24%, respectively, with bone scan.
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PET has emerged in the last decade as an important tool 
in the staging and delineation of disease for conformal radio-
therapy planning of non-SCLC. In 2009, Medicare approved 
the use of PET for the initial staging of SCLC.3 Medicare 
allows a significantly higher national average fee for whole-
body PET ($1020, CPT 78816) relative to bone scan ($206, 
CPT 78315). Yet PET’s role in SCLC remains unclear.2
It is believed that PET may more accurately detect 
patients with extensive-stage disease than CT-staging alone.4 
This stage migration allows physicians to withhold potentially 
toxic radiation therapy from poorer prognosis extensive-stage 
patients who would not benefit from it (Fig. 1A). With better 
ability to identify patients who will likely respond to treat-
ment, stage-specific survival will improve.5
At the same time, PET may demonstrate with greater 
accuracy the extent of intrathoracic tumor and nodal disease 
(Fig. 1B). Improved treatment targeting may result in improved 
local disease control, which may translate into a real sur-
vival increment.We hypothesize that the addition of PET to 
CT staging is associated with improved progression-free and 
overall survival in patients with SCLC. To our knowledge, no 
one has yet reported an association between the use of PET 
and survival in SCLC.2
PATIENTS AND METHODS
Patient Inclusion Criteria
With the University of Pennsylvania Institutional 
Review Board approval, we identified 54 LS-SCLC patients 
consecutively treated with definitive concurrent chemoradiation 
from January 2002 to August 2010. Patient staging was based 
on all available pathologic and radiographic studies, including 
FIGURE 1. A, PET can identify extratho-
racic disease (blue circle) not seen on other 
staging studies (e.g., CT), B, PET can also 
uniquely identify intrathoracic disease (blue 
circle), and disease seen on other studies 
(red circle). CT, computed tomography; 
PET, positron emission tomography.
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CT, PET, magnetic resonance imaging (MRI), and bone 
scintigraphy. None of the patients received surgery, CT of the 
brain (all patients underwent cranial MRI imaging),or a bone 
marrow biopsy.
Patient Diagnosis and Follow-up
All patients had a complete history, that is a physical 
examination, abdominothoracopelvic CT with or without PET 
scan, and a brain CT or MRI, at diagnosis. All patients had 
pathologically confirmed small-cell lung carcinoma. Since 
2002 it has been an institutional practice to include PET in 
staging, when possible. However, the recently treated patients 
in this study were more likely to undergo PET staging because 
of changes in reimbursement for PET in SCLC.
The standard staging approach for SCLC patients is 
to classify them as having a limited- or extensive-stage dis-
ease. Limited-stage disease is defined as disease that can 
be  encompassed within a tolerable radiation portal. For this 
study, we further assigned each patient a TNM stage, on the 
basis of the American Joint Committee on Cancer Staging 
Manual, 7th edition.
N status was determined primarily by size and morpho-
logic criteria as interpreted by the lead radiologist. None of the 
patients in the study underwent mediastinoscopy. In general, 
suspicious nodes were defined as those clearly visible above 
the mediastinal background on PET. These nodes were then 
compared with the CT for benign findings, such as nodes 
that had a very small short axis or fatty hilum. Although no 
rigorous criteria were used, maximum standard uptake value 
corrected for body weight greater than 2 or 3 and node axes 
greater than 1 cm prompted closer scrutiny. Ultimately, clini-
cal judgment was applied for marginal cases. Two radiologists 
reviewed each case and were in agreement on the staging.
After treatment, standard chest CT and/or PET scans 
were used to evaluate for disease recurrence. Patients were fol-
lowed up approximately every 3 months for the first 1 to 3 years 
after treatment and every 6 to 12 months thereafter. All patients 
had a minimum of 6 months’ follow-up postradiotherapy.
Treatment Techniques and Parameters
The gross tumor volume (GTV) consisted of all known 
sites of primary and nodal thoracic disease based on imaging 
findings and pathologic staging. For patients who underwent 
four-dimensional (4D)-CT planning, an internal GTV was 
generated based on the motion envelope of the GTV. A clini-
cal target volume (CTV) expansion of 0.8 cm was added to the 
internal GTV to treat regions at risk for microscopic spread 
of tumor. For patients who did not undergo 4D-CT planning, 
the GTV was expanded by 1.5 cm for lower lobe tumors and 
1.0 cm for upper lobe tumors, to generate the CTV. A uniform 
planning target volume expansion of 0.5 cm was then applied 
to the CTV to account for setup error.
Most patients (85%) received 0.150 Gy twice-daily 
fractions to 45 Gy, and patients who could not tolerate twice-
daily treatments, received 0.180 Gy once a day to 56-72 Gy. 
We delivered the maximally safe dosage to the planning target 
volume while constraining the lung to the following param-
eters: V20 35% or lesser, V5 60% or lesser, and mean lung 
dosage less than or equal to 20 Gy. In patients for whom once-
daily treatment was delivered, the final prescription dosage 
was based upon several factors, including dosimetric con-
straints and performance status.
Chemotherapy
All patients received at least one cycle of either con-
current or sequential chemotherapy. Patients usually received 
cisplatin or carboplatin in combination with another chemo-
therapeutic agent, typically etoposide (Table 1).
Local Control Evaluation
Tumor burden and response were scored using the 
guidelines established by the revised Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.1.
Statistical Analysis
Patient comorbidities were assessed using the Charlson 
comorbidity index. The index predicts the 10-year mortality 
for patients based on their comorbidity profile. We assigned 
one, two, three, or six points to more than 20 conditions, based 
on the risk of dying from each one, using the scale below. We 
then summed the total score to assess mortality.
•  One point: myocardial infarction, congestive heart fail-
ure, peripheral vascular disease, dementia, uncompli-
cated diabetes, cerebrovascular disease, chronic lung 
disease, connective tissue disease, ulcer, and chronic 
liver disease without portal hypertension.
•  Two points: hemiplegia, moderate or severe kidney dis-
ease, diabetes with end organ disease, local malignancy, 
and lymphoma.
•  Three points: moderate or severe liver disease.
•  Six points: metastatic tumor or acquired immunodefi-
ciency syndrome.
Each subject’s overall survival was computed from the 
date of diagnosis by imaging (or date of first treatment for a 
parallel analysis) until death or date of last follow-up when 
they were censored. We used Kaplan–Meier and log-rank test-
ing to compare unadjusted survival profiles. Cox proportional 
hazards regression controlled for potential confounders. Any 
variable with p value of 0.10 or lesser in the univariate model 
was eligible for multivariable Cox modeling. A threshold of p 
value lesser than or equal to 0.05 established significance on 
multivariate analysis.
We examined local and distant control rates using two 
different methodologies. First, we report unadjusted local 
and distant control rates on any event basis. This approach 
includes all patients in the control analysis, regardless of 
whether they previously had a distant failure and vice versa. 
Second, we report the local and distant control rates on a first-
event basis while adjusting for the competing risk of death 
using nonparametric cumulative incidence functions.6
We used Cox regression to identify individual covariates 
associated with survival and to adjust for potential confound-
ers. Any covariate with a univariate p value of 0.10 or lesser 
was included in the model. We used the Schoenfeld residuals 
test to verify the underlying proportional hazards assumption.
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We compared the distribution of patient characteris-
tics between the two treatment groups with Pearson’s χ2 test, 
Fisher’s exact test, or nonparametric equality of medians test.
Descriptive statistics were performed on STATA/IC 
(version 11.0 for Mac OS X; StataCorp, College Station, 
TX). Competing risk analysis was conducted using R (version 
2.15.0 Mac OS X; R Foundation for Statistical Computing, 
Vienna, Austria).
RESULTS
Characteristics
Our study included 54 LS-SCLC patients. Table 1 shows 
the distribution of patient characteristics among patients 
staged with and without 18F-fluorodeoxyglucose (FDG) PET. 
The two cohorts had similar age, race, sex, performance sta-
tus, T-stage, lung lobe involvement, tumor laterality, comor-
bidities, proportion staged with bone scan, median time from 
diagnosis to start of radiation, percentages of patients who 
started radiation while hospitalized, chemotherapy regimens 
and cycles, and proportion of patients who received pro-
phylactic cranial and (postmetastatic) whole-brain radiation 
therapy. Both groups received similar prescription dosages 
(median 4500 cGy) and number of daily fractions.
PET-staged patients had significant differences in 
N-staging at diagnosis compared with those staged with CT 
alone. PET-staged patients were more likely to have any nodal 
metastasis (74% versus 50%) and advanced N3 nodal metas-
tasis (10% versus 0%) at diagnosis. There was a trend for 
recently treated patients to undergo PET staging (PET-staged 
median treatment year = 2008 versus CT-stage median = 
2006; p = 0.12).
Survival and Local Control
Median follow-up was 38 months (range, 14–97 
months) in the 19 surviving PET-staged patients and 40 
months in the two surviving non-PET-staged patients (range, 
29–51 months; p = 0.59). LS-SCLC patients who underwent 
PET as a part of initial staging had significantly improved 
survival compared with those who did not. PET-staged 
patients had a higher median overall survival of 32 months 
(95% confidence intervals [CI]: ≥24) compared with 17 
months (95% CI: 11–32) in all patients not staged with PET 
(p = 0.03) (Fig. 2). Median survival did not change (32 ver-
sus 17 months; p = 0.03) even after excluding the five non-
PET-staged patients who did not receive a bone scan either. 
Patients staged with PET also had an improved 1-year (75% 
versus 64%) and 3-year (47% versus 19%) overall survival 
rates (p = 0.03) from time of diagnosis.
PET staging was associated with longer time-to-distant 
failure. On an unadjusted any-event basis, PET-staged patients 
had median time-to-distant failure of 29 months (95% CI 
≥18) compared with 11 months (95% CI: 4–16) in patients 
not staged with PET (p < 0.01) (Fig. 3A). After adjusting for 
the competing risk of death on a first event basis, PET-staged 
patients had median time-to-distant failure of 29 months 
compared with 12 months in patients not staged with PET 
(p = 0.04) (Fig. 4A).
TABLE 1.  Patient Characteristics
Patient Characteristic
No PET
(n = 14)
PET
(n = 40) p
Median age, yrs (range) 59 (41–77) 67 (41–79) 0.35
Race (all), % (n) 0.41
 White 62% (8) 77% (30) 0.28
 Black 23% (3) 18% (7) —
 Other 15% (2) 5% (2) —
 Unknown (1) (1) —
Women, % (n) 79% (11) 78% (31) 0.93
ECOG (all), % (n) 0.85
 0 21% (3) 15% (6)
 1 57% (8) 60% (24)
 2 21% (3) 25% (10)
T (all), % (n) 0.17
 1 33% (3) 39% (15) —
 2 56% (5) 21% (8) —
 3 0% (0) 11% (4) —
 4 11% (1) 29% (11) —
 Unknown (5) (2) —
N (all), % (n) 0.05
 0 50% (7) 26% (10) —
 1 0% (0) 13% (5) —
 2 50% (7) 34% (13) —
 3 0% (0) 26% (10) —
 Unknown (0) (2)
Lobe (all), % (n) 0.09
 Upper 62% (8) 82% (28) —
 Middle 15% (2) 0% (0) —
 Lower 23% (3) 15% (5) —
 Multiple 0% (0) 3% (1) —
 Unknown (1) (6) —
Laterality (all), % (n) 0.31
 Right 69% (9) 53% (18) —
 Left 30% (4) 47% (16) —
 Unknown (1) (6) —
Charlson index, median (range) 2 (2–8) 3 (2–5) 0.81
Bone scan staging, % (n) 64% (9) 35% (14) 0.06
Median treatment start, yr 2006 2008 0.12
Median days from diagnosis to 
radiation start, median (range)
35 (17–50) 34 (5–178) 0.11
Median dosage, Gy (range) 45 (45–59) 45 (45–72) 0.74
Twice-daily fractions, % (n) 93% (13) 84% (33) 0.44
Inpatient radiation start, % (n) 14% (2) 5% (2) 0.25
Concurrent chemotherapy 0.24
 Carboplatin/etoposide 0% (0) 3% (1)
 Carboplatin/irinotecan 10% (1) 0% (0)
 Carboplatin/paclitaxel 0% (0) 3% (1)
 Cisplatin/etoposide 93% (13) 95% (34)
Chemotherapy cycles, median (range) 4 (1–4) 4 (3–12) 0.92
Prophylactic cranial irradiation, % (n) 64% (9) 73% (29) 0.33
Median dosage,Gy (range) 30 (24–36) 25 (25–36)
Whole-brain radiation therapy, % (n) 8% (1) 8% (3) 0.94
 Unknown (2) (2)
ECOG, Eastern Cooperative Oncology Group; PET, positron emission tomography.
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PET staging was also associated with time-to-local fail-
ure. On an unadjusted any event basis, PET-staged patients 
did not reach their median time-to-local failure compared 
with 26 months (95% CI ≥9) in patients not staged with PET 
(p = 0.05) (Fig. 3B). After adjusting for the competing risk 
of death on a first event basis, PET-staged patients still did 
not reach their median time-to-local failure compared with 
16 months in patients not staged with PET (p = 0.04) (Fig. 4B).
On multivariate analysis, PET staging (odds ratio 
[OR] = 0.24; p = 0.04), performance status (OR = 1.89; 
p = 0.05), and N-stage (OR = 4.94; p <0.01) were significantly 
associated with overall survival. Table 2 shows all the covari-
ates adjusted for in the Cox model.
FIGURE 2.  Kaplan–Meier analysis of overall survival from 
diagnosis (p = 0.03).
FIGURE 3.  Kaplan–Meier analysis of (A) unadjusted any 
event distant control (p < 0.01); (B), unadjusted any event 
local control (p = 0.05).
FIGURE 4.  Cumulative incidence functions adjusting for the 
competing risk of death in first event (A) distant (p = 0.04); 
and (B), local (p = 0.04) failure.
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DISCUSSION
Pretreatment PET staging of LS-SCLC was associated 
with improved survival. PET-staged patients had an improved 
3-year overall survival from diagnosis (47% versus 19%; 
p = 0.03) compared with those with LS-SCLC who were not 
staged with PET. They also had longer times-to-local and dis-
tant failures. PET’s ability to (1) foster stage migration that 
accurately distinguishes limited- from extensive-stage patients 
(Fig. 1A), and (2) more 
thoroughly identify intrathoracic disease for radia-
tion treatment planning (Fig. 1B) may, in part, explain these 
observed differences between the two treatment groups.
To our knowledge, this is the first study to report on 
overall and disease-free survival in SCLC patients staged 
with and without PET. A number of earlier studies have 
shown that PET added to conventional staging has better sen-
sitivity detecting sites of local- and distant-disease involve-
ment than conventional staging alone.2,4,7–10 Prior studies have 
also shown high occurrences of patient management changes 
attributed to PET.4,7,8,11,12 But these studies have not shown that 
an association between PET staging and management changes 
are associated with a survival benefit. Additional, prospective 
investigation would help confirm the survival benefit of PET 
staging demonstrated in this study. Although a number of 
prospective trials—including the Ontarion Clinical Oncology 
Group (OCOG) Impact of Positron Emission Tomography 
in Stage III Non-Small Cell Lung Cancer: A Prospective 
Randomized Trial (PET START) by Ung et al.13—are or will 
be investigating the role of PET in non-SCLC,13–17 none have 
been commissioned for SCLC.
In addition to PET staging, several other factors are 
associated with survival. Echoing earlier series, poorer per-
formance status (OR = 1.89; p = 0.05),18,19 and nodal metasta-
ses at diagnosis (OR = 4.54; p < 0.01)19 were associated with 
worse survival in this study. Other factors—including age, 
race, sex, and the proportion of patients with bone and head 
scans—were well balanced across the treatment groups and 
did not readily explain the observed local control, distant con-
trol, and survival differences (Table 1).
We next investigated whether confounders could explain 
the observed survival difference. Most characteristics were 
well balanced across the treatment groups and did not read-
ily explain the survival gap. But the two groups did differ in 
one respect: They had a significantly different distribution of 
nodal disease at diagnosis (p = 0.05), with PET-staged patients 
more likely diagnosed with any nodal metastasis (74% versus 
50%) and advanced N3 nodal metastasis (10% versus 0%). 
This, however, harmonized with previous reports, indicating 
that staging without PET underdiagnosed mediastinal lymph 
node disease, and most likely did not drive the survival decre-
ment in the two groups.2,7–9
Besides being associated with overall survival, PET 
staging was associated with increased local and distant pro-
gression-free survival. PET-staged patients experienced dis-
tant failure less rapidly than those who were not (median 
29 versus 12 months on a first-event basis adjusting for the 
competing risk of death; p = 0.04) (Fig. 4A). Several studies 
have shown PET’s superior ability to identify distant disease, 
particularly osseous metastases (Fig. 1).2,20,21 Some patients 
not staged with PET may have had microscopic or otherwise 
occult distant disease not detected during their initial staging 
with CT alone. As a result, these patients seem to develop dis-
tant progression faster than their PET-staged counterparts.
Likewise, PET-staged patients progressed to local fail-
ure less quickly than those who were not staged with PET 
(median not reached versus 16 months on first-event basis 
adjusting for competing risk of death; p = 0.04) (Fig. 4B). 
PET’s ability to identify more accurately the full extent of dis-
ease at diagnosis may explain why. Numerous studies have 
shown the difficulties of identifying the primary tumor’s full 
extent without PET staging (Fig. 2).2,4,7–10,22 If hard-to-detect 
regions like these were not specifically targeted for treatment, 
local failure rates might increase, and as uncontrolled disease 
progressed, it would give the illusion of a shorter time to local 
failure in patients not staged with PET.
As in any retrospective study, selection bias because of 
unmeasured confounders may explain the potentially worse 
survival rate in patients staged without PET. For example, 
although more recently diagnosed patients were more likely 
to undergo PET staging (PET-staged median treatment year 
2008) than patients treated in the more distant past (CT-stage 
median 2006; p = 0.12), there was some overlap. It is unclear 
how insurance coverage—a possible proxy for socioeconomic 
status—compared across the two cohorts. At the same time, 
although the fundamental therapeutic approach has remained 
the same, improvements in technology over the 6-year study 
span may have confounded the observed association between 
PET staging and survival: Beginning in 2008, we began to 
use four-dimensional treatment planning in many of our 
LC patients to account for tumor respiratory motion during 
radiation delivery. But as noted earlier, patients treated after 
2008 also had a significantly greater likelihood of undergo-
ing PET staging. Separately, other possible indicia of dis-
ease severity, such as serum alkaline phosphatase and lactate 
TABLE 2.  Uni- and Multivariable Cox Survival Analysis
OR (95% CI, p) 
(Univariate)
OR (95% CI, p)  
(Multivariate)
PET staged (yes/no) 0.47 (0.23–0.97, 0.04) 0.25 (0.11–0.56, <0.01)
Median age (>64.5 yrs, 
yes/no)
0.93 (0.47–1.85, 0.84) —
ECOG (0 vs. 1 vs. 2) 1.84 (1.05–3.24, 0.04) 1.87 (1.01–3.48, 0.05)
Left-based primary 
(yes/no)
0.62 (0.29–1.32, 0.20) —
Upper-lobe–based 
primary (yes/no)
1.50 (0.57–3.95, 0.41) —
Women (yes/no) 1.42 (0.59–3.45, 0.47) —
White (yes/no) 0.74 (0.33–1.65, 0.47) —
T-stage (1 vs. 2 vs. 3 
vs. 4)
1.27 (0.94–1.70, 0.12) —
N (>N0, yes/no) 2.95 (1.30–6.69, 0.01) 4.75 (1.89–11.94, <0.01)
Bone scan (yes/no) 1.52 (0.77–3.02, 0.23) —
CI, confidence intervals; OR, odds ratio; PET, positron emission tomography.
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dehydrogenase, were not sufficiently available for comparison 
across the two groups. Finally, although most patients in both 
groups received a platin with etoposide, it is impossible in a 
retrospective study to exactly match chemotherapy across the 
treatment groups. These potential biases mean that interpreta-
tion of our data should be viewed as preliminary, and larger 
studies are needed to confirm our findings.
CONCLUSION
The addition of PET in the routine staging of SCLC 
seems to be associated with improved time-to-local and distant 
failure and overall survival. These findings are likely attributed 
to more accurate extra- and intrathoracic staging of SCLC with 
PET, and underscore its value in staging of patients with SCLC.
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